|
1. BIOLOGIE
|
|
|
|
1.1 BIOLOGIE - GÉNOME
|
|
|
|
4.15 DÉP., DIAG. & PRONO. - IMAGERIE
|
|
|
|
4.3 DÉP., DIAG. & PRONO. - INDUSTRIELS
|
|
|
|
5.1 TRAITEMENTS - PRÉ-CLINIQUE
|
|
|
Game theory suggests more efficient cancer therapy [Cornell]
|
|
|
|
|
|
Cancer cells not only ravage the body – they also compete with each other. Cornell mathematicians are using game theory to model how this competition could be leveraged, so cancer treatment – which also takes a toll on the patient’s body – might be administered more sparingly, with maximized effect.
|
|
|
|
|
|
|
5.10 TRAITEMENTS - ESSAIS
|
|
|
|
5.12.11 IMMUNOTHÉRAPIES - PRÉ-CLINIQUE
|
|
|
|
|
5.12.2 IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES
|
|
|
NCI Initiative Aims to Boost CAR T-Cell Therapy Clinical Trials [NCI]
|
|
|
|
|
|
The initial clinical trial supported by this effort will be the first trial to test a CAR T-cell therapy designed to target a protein on cancer cells called CD33 in children and young adults with advanced forms of acute myeloid leukemia (AML). It will ultimately enroll patients at six different sites, starting at the NIH Clinical Center in Bethesda, MD, and the Children’s Hospital of Philadelphia (CHOP).
|
|
|
|
|
|
|
5.12.5 IMMUNOTHÉRAPIES - PHARMA
|
|
|
|
|
5.17 TRAITEMENTS - RADIOTHÉRAPIE
|
|
|
|
5.2 PHARMA
|
|
|
|
|
5.2.3 PHARMA - ÉCONOMIE
|
|
|
|
5.2.6 PHARMA - BIOTECH
|
|
|
|
5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)
|
|
|
|
|
|
Immunomedics Triple Negative Breast Cancer Drug Wins Early FDA Nod [Xconomy]
|
|
|
|
|
|
Drugs reviewed on an accelerated basis still need to show additional clinical data in order to keep their approval. Two weeks ago, Immunomedics announced that a Phase 3 clinical trial that enrolled more than 500 patients is stopping early after an independent committee reviewing the study’s data found that the drug provided “compelling evidence of efficacy.”
|
|
|
|
|
|
|
|
|
5.9 AACR
|
|
|
|
AACR 2020 preview – no Tigit, but plenty of novel mechanisms [Evaluate]
|
|
|
|
|
|
Unveiling of the presentation titles for the first instalment of this year’s AACR meeting has revealed two surprises: the absence of keenly awaited clinical data on Roche’s anti-Tigit MAb tiragolumab, and the presence of a trio of studies on Ox40, an immuno-oncology target that had earlier fallen out of favour.
|
|
|
|
|
|
|
6.15 LUTTE CONTRE LES CANCERS - COVID-19
|
|
|